A lightweight cerebrospinal fluid biomarker-based model for first-diagnosis prediction of Parkinson's disease: model development, external validation, and local deployment

基于脑脊液生物标志物的轻量级帕金森病首诊预测模型:模型开发、外部验证和本地部署

阅读:2

Abstract

BACKGROUND: Despite substantial progress in biomarker research, Parkinson's disease (PD) still lacks widely validated, easily deployable diagnostic tests for reliable early-stage detection, particularly in resource-limited circumstances. OBJECTIVE: This study aimed to develop and externally validate a lightweight machine learning model for the first-diagnosis prediction of PD using baseline cerebrospinal fluid (CSF) biomarkers from the Parkinson's Progression Markers Initiative (PPMI). METHODS: Baseline CSF data from 665 participants (PD = 415, controls = 190, SWEDD = 60) were used. Five machine learning classifiers-L2-regularized logistic regression (L2-LR), random forest (RF), histogram-based gradient boosting (HistGB), support vector machine with RBF kernel (SVM-RBF), and multilayer perceptron (MLP)-were trained and compared. Feature selection focused on five core CSF biomarkers (Aβ42, α-synuclein, total tau, phosphorylated tau181 and hemoglobin). Model performance was evaluated using AUC, PR-AUC, and Brier scores, followed by isotonic calibration and independent validation using the University of Pennsylvania dataset. RESULTS: A lightweight, biomarker-based RF model effectively distinguishes first-diagnosis PD cases using limited baseline CSF indicators. Its offline Streamlit deployment offers a practical tool for resource-limited settings, bridging the gap between computational prediction and real-world neurological diagnosis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。